World's first mRNA flu vaccine approved: What it means for adults over 50

The United States has approved the world's first mRNA-based seasonal influenza vaccine, marking a major milestone in vaccine technology beyond COVID-19. The vaccine, mFlusiva, developed by Moderna, has received approval from the US Food and Drug Administration (FDA) for adults aged 50 years and above.

Experts believe the breakthrough could significantly improve how annual flu vaccines are developed by enabling faster production and better adaptation to rapidly changing influenza virus strains.

US FDA approves first mRNA seasonal flu vaccine

The FDA approval covers:

• Full approval for adults aged 50 to 64 years
• Accelerated approval for adults 65 years and older, with Moderna required to conduct additional studies to confirm long-term clinical benefits

Unlike traditional flu vaccines produced using eggs or cell cultures, mFlusiva uses messenger RNA (mRNA) technology, the same platform that gained global recognition during the COVID-19 pandemic.

How does an mRNA flu vaccine work?

Traditional influenza vaccines introduce weakened or inactive virus particles to train the immune system.

An mRNA vaccine works differently. It delivers genetic instructions that prompt the body's cells to temporarily produce a harmless influenza protein. The immune system then recognises this protein as foreign and develops antibodies and immune responses that can protect against future influenza infections.

Importantly, the vaccine does not contain a live influenza virus, meaning it cannot cause the flu.

Why this approval is significant

Influenza viruses mutate constantly, requiring vaccine formulations to be updated every year.

Conventional vaccine production can take several months, limiting flexibility if circulating virus strains change during manufacturing.

Researchers say mRNA technology offers several advantages:

• Faster vaccine development
• Rapid large-scale manufacturing
• Easier updates for emerging flu strains
• Better matching of vaccines to circulating viruses
• Potentially stronger immune responses in high-risk populations

These advantages could improve the effectiveness of annual influenza vaccination programmes worldwide.

Clinical trial results

The FDA's decision was based on a Phase 3 clinical trial involving more than 40,000 adults aged 50 years and older.

According to Moderna, the vaccine:

• Reduced laboratory-confirmed influenza cases by 26.6% compared with a standard licensed flu vaccine
• Generated stronger immune responses than Sanofi's high-dose influenza vaccine among older adults

However, further studies are required to confirm whether these stronger immune responses translate into better long-term protection for adults aged 65 years and above.

Why older adults are at greater risk

People over 50, especially seniors, face a higher risk of severe influenza because immune function naturally declines with age.

Complications can include:

• Pneumonia
• Hospitalisation
• Worsening heart or lung disease
• Influenza-related deaths

According to the World Health Organization (WHO), seasonal influenza causes 3–5 million severe illnesses and up to 650,000 respiratory deaths globally each year, making effective vaccination a critical public health measure.

What does this mean for India?

The approval currently applies only to the United States.

India already offers licensed seasonal influenza vaccines for high-risk groups, including:

• Older adults
• Pregnant women
• Healthcare workers
• Individuals with chronic medical conditions

Whether mRNA-based influenza vaccines become available in India will depend on approvals from Indian regulatory authorities and future policy decisions. At present, India's influenza vaccination recommendations remain unchanged.

A new chapter in vaccine science

Scientists view the approval of mFlusiva as an important step in expanding the use of mRNA technology beyond COVID-19.

Researchers are already studying mRNA-based vaccines for several infectious diseases and even certain cancers. If ongoing studies continue to demonstrate strong effectiveness, mRNA vaccines could become a key part of future seasonal influenza prevention strategies worldwide.

The approval signals a significant advancement in vaccine development and highlights how emerging technologies may help improve protection against rapidly evolving viruses.